Effrx Pharmaceuticals Sa

Lean and Agile Integrated Market-Oriented Biopharma Focused on Niche Therapeutics in Europe: EffRx Pharmaceuticals is a commercial-stage pharmaceutical company focused on the late-stage development and commercialization of prescription medications for niche and orphan indications. The business model is centered around providing superior clinical and commercial value propositions for physicians, payers and patients. EffRx pro-actively seeks in-licensing opportunities for Europe in niche therapeutic areas, with a primary interest for rare diseases, where EffRx has received an orphan drug designation (ODD) from FDA for a pipeline asset. EffRx is a member of the World Orphan Drug Alliance (WODA). WODA provides full-service solution to pharmaceutical & biotech companies with a portfolio of rare diseases, oncology and highly specialized therapeutics, starting from named patient programs to full commercialization. EffRx’s go-to-market competence is proven by the development, launch and expansion of Binosto® in a highly competitive European market. Binosto®, indicated for the treatment of osteoporosis, is marketed in the US as well as selected European and Asian countries.